**Core Concept:** Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolysis of the sn-2 position of phospholipids, releasing fatty acids and lysophospholipids. Inhibition of PLA2 is a therapeutic strategy for various conditions, such as inflammation and neurodegenerative disorders.

**Why the Correct Answer is Right:**

The correct answer, **D** (Nicotinic Acid or Vitamin B3), reduces the activity of phospholipase A2 through its role in the synthesis of coenzyme A, a crucial enzyme for the activation of PLA2. Nicotinic acid is the active form of Vitamin B3, and its administration leads to increased coenzyme A levels, thereby decreasing PLA2 activity and its downstream effects.

**Why Each Wrong Option is Incorrect:**

A. **Option A (Diclofenac):** Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that primarily targets cyclooxygenase (COX) enzymes, responsible for prostaglandin synthesis. Diclofenac does not directly inhibit phospholipase A2.

B. **Option B (Ibuprofen):** Similar to option A, ibuprofen primarily targets COX enzymes, not phospholipase A2.

C. **Option C (Salicylic Acid):** Salicylic acid is the active moiety in aspirin (salicylic acid + salicylic acid esterase). Aspirin primarily inhibits COX enzymes, not phospholipase A2.

**Clinical Pearl:**

Phospholipase A2 inhibitors, such as nicotinic acid, are used in the treatment of inflammatory disorders and neurodegenerative diseases due to their ability to reduce PLA2 activity and subsequent inflammation. However, these drugs are not commonly used as a first-line therapy, as they target a specific pathway (PLA2) while ignoring other key inflammatory mediators (e.g., COX enzymes).